Recombinant meningococcal group B vaccine (Sanroad Biological Produ…

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Not Applicable

Clinical phase

Completed

Recruitment status

104

Planned enrollment

2026-07-20

Primary-completion proxy

Executive view

NCT07784452 evaluates Recombinant meningococcal group B vaccine (Sanroad Biological Products) in Hepatitis B. The disclosed sponsor is Jinnah Hospital Lahore, the design is Interventional, and the geographic footprint is Pakistan. The first listed primary endpoint is Proportion of Participants Achieving Seroprotection (Anti-HBs Titer ≥10 mIU/mL), assessed over 30 days after completion of the assigned vaccination schedule (Month 7 for 3-dose group; Month 7 for 4-dose group).

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07784452 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Hepatitis B landscape. Drug & Asset MCP drug_fetch was queried for Recombinant meningococcal group B vaccine (Sanroad Biological Products), while Company & Deal Intelligence MCP organization_fetch was queried for Jinnah Hospital Lahore.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07784452	Recombinant meningococcal group B vaccine (Sanroad Biological Products)	Not Applicable / Completed	Jinnah Hospital Lahore	Pakistan	Proportion of Participants Achieving Seroprotection (Anti-HBs Titer ≥10 mIU/mL) 30 days after completion of the assigned vaccination schedule (Month…	2026-07-20
NCT07786571	Dorzagliatin	Not Applicable / Not yet recruiting	Sun Yat-Sen University	China	Change in Time in Range (TIR, 3.9-10.0 mmol/L) from baseline to Week 14 Baseline to Week 14	2029-03-01
NCT07786168	Roxadustat	Not Applicable / Completed	Shaikh Zayed Hospital	Pakistan	Change in Hemoglobin Level From Baseline to 3 Months Baseline to 3 months	2026-06-20
NCT07781020	Mecobalamin	Not Applicable / Completed	Jinnah Hospital Lahore	Pakistan	Change in Serum Vitamin B12 Level from Baseline to Week 5 Baseline and Week 5 (one week after completion of the 4-week interven…	2026-05-22
NCT07775482	Finerenone	Not Applicable / Not yet recruiting	Sponsor not reported	Canada	Recruitment success 2 years from first participant recruited	2029-01-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07784452 is a Not Applicable, completed study with 104 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.

The primary endpoint is “Proportion of Participants Achieving Seroprotection (Anti-HBs Titer ≥10 mIU/mL)” over “30 days after completion of the assigned vaccination schedule (Month 7 for 3-dose group; Month 7 for 4-dose group).” The retrieved endpoint description is: Seroprotection will be assessed by measuring serum Hepatitis B surface antibody (Anti-HBs) titers using a quantitative chemiluminescence immunoassay. A titer of ≥10 mIU/mL will be defined as seroprotection. The proportion of participants achieving seroprotection will be compared between the 3-dose and 4-dose vaccination schedule groups..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 104 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Hepatitis B. These records do not establish direct evidence for NCT07784452 unless the registration number matches.

Hydroxychloroquine for the Management of CVD in CKD

Phase 2; n=100; Baseline(Mean) = 1674.38 mm3 (Standard Deviation, 439.89); Baseline(Mean) = 1498.57 mm3 (Standard Deviation, 341.54) Source: https://clinicaltrials.gov/ct2/show/results/NCT03636152

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Quarterly and Monthly TOUR006 in Participants With Chronic Kidney Disease and Elevated High-Sensitivity C…

Phase 2; n=143; Time-Averaged Percent Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Through Day 90(Median) = -14.8 Time-Averaged Percent Change in hsCRP (Inter-Quartile Range, -35.8 to 17.4); Time-Averaged Percent Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Through Day 90(Median): Median Difference (Net) = -59.817(95% CI, -79.690 to -39.943), P-Value = <0.0001; Median Difference (Net)… Source: https://clinicaltrials.gov/ct2/show/results/NCT06362759

Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent…

Phase 3; n=211; EFFICACY: MATE-3 Score(Mean) = 0.9 Scores on a scale (Standard Deviation, 2.2); EFFICACY: MATE-3 Score(Mean): Mean Difference (Net) = -0.32(95% CI, -0.90 to 0.20), P-Value = 0.16 Source: https://clinicaltrials.gov/ct2/show/results/NCT03386539

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

No exact Drug & Asset MCP profile was returned for the protocol wording “Recombinant meningococcal group B vaccine (Sanroad Biological Products).” The report therefore avoids inferring modality, target or global development stage from the name alone.

Jinnah Hospital Lahore is indexed in Pakistan. The organization record is used to resolve sponsor identity. The record lists an unreported number of development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Recombinant meningococcal group B vaccine (Sanroad Biological Products) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07784452
Protocol source: https://clinicaltrials.gov/study/NCT07784452
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.

Recombinant meningococcal group B vaccine (Sanroad Biological Products) in Hepatitis B is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Proportion of Participants Achieving Seroprotection (Anti-HBs Titer ≥10 mIU/mL) and 2026-07-20 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP